Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
RBC Capital Out Positive on Neumora Therapeutics (NMRA): ' See Compelling Entry Point Ahead of Key 2H24 Catalysts'
March 13, 2024 12:07 PM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $31.00 price target on Neumora Therapeutics (NASDAQ: NMRA).
The analyst comments "This morning, shares of NMRA are down substantially (~17%, vs. XBI +1%); we have not found any fundamental reasons for today's weakness, but do note that today is the expiration of lock-up agreements in connection with their September 2023 IPO. We would view any... More
